Curium Belgium

Curium is a global leader in the radiopharmaceutical industry, specializing in the development, manufacture, and distribution of high-quality diagnostic and therapeutic agents. Formed through the merger of IBA Molecular and Mallinckrodt Nuclear Medicine, the company maintains a significant presence in Belgium with a major production facility in Fleurus. Curium's extensive portfolio supports over 14 million patients annually across oncology, cardiology, and neurology. The company is a pioneer in the theranostics approach, providing both imaging agents for diagnosis and targeted radioligand therapies for treatment. With a robust global supply chain, Curium ensures the reliable delivery of short-lived isotopes to hospitals and clinics worldwide.